M. I. Taskin Et Al. , "Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist," GYNECOLOGICAL ENDOCRINOLOGY , vol.31, pp.949-954, 2015
Taskin, M. I. Et Al. 2015. Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist. GYNECOLOGICAL ENDOCRINOLOGY , vol.31 , 949-954.
Taskin, M. I., Topcu, O., Yay, A. H., Erken, G., Balcıoğlu, E., Adali, E., ... Hismiogullari, A. A.(2015). Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist. GYNECOLOGICAL ENDOCRINOLOGY , vol.31, 949-954.
Taskin, Mine Et Al. "Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist," GYNECOLOGICAL ENDOCRINOLOGY , vol.31, 949-954, 2015
Taskin, Mine I. Et Al. "Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist." GYNECOLOGICAL ENDOCRINOLOGY , vol.31, pp.949-954, 2015
Taskin, M. I. Et Al. (2015) . "Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist." GYNECOLOGICAL ENDOCRINOLOGY , vol.31, pp.949-954.
@article{article, author={Mine Islimye Taskin Et Al. }, title={Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist}, journal={GYNECOLOGICAL ENDOCRINOLOGY}, year=2015, pages={949-954} }